MMED:CC News and Press, MIND MEDICINE INC. From 11/10/22

In recent years, emerging studies involving psychedelics have found that hallucinogenic drugs can be effective at treating a variety of mental health conditions . These clinical trials and studies have revealed that when paired with psychotherapy, psychedelics can result in positive and pro...

MindMed Reports Third Quarter 2022 Financial Results and Business Highlights Canada NewsWire – Initiated Phase 2b dose-optimization trial in patients with Generalized Anxiety Disorder, with first patients dosed in Q3 2022 and key clinical readout expected in...

DiPT (N,N-diisopropyltryptamine) is a psychedelic drug of the tryptamine family that induces auditory hallucinations. This means that unlike other hallucinogens which cause visual hallucinations by affecting an individual’s visual sense, DiPT causes hallucinations where an individu...

MindMed to Host Earnings Call to Discuss Third Quarter 2022 Financial Results and Provide Business Update Canada NewsWire NEW YORK , Nov. 3, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clini...

New research has found that the use of psychedelic substances is not linked to the lifetime development of cancer. The investigators’ objective was focused on determining whether there was any truth to research from the 1960s that associated the use of psychedelics to a heightened r...

Novel psychedelic drugs have continuously proven their worth in clinical trials. Just recently, one company revealed that it was in the process of finalizing its Phase 1 first-in-human clinical trial plan for its lead psychedelic drug for the treatment of major depressive disorder after r...

MindMed to Participate in the Cantor Fitzgerald Neurology & Psychiatry Conference MindMed to Participate in the Cantor Fitzgerald Neurology & Psychiatry Conference Canada NewsWire NEW YORK , Oct. 5, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (...

MindMed Collaborators Initiate Phase 1 Comparative PK/PD Trial of R-, S- and Racemic MDMA Canada NewsWire - Study will compare the acute subjective, physiological, and endocrine effects of R-MDMA, S-MDMA, and racemic MDMA in 24 healthy subjects - NEW YORK , ...

We have seen interest in psychedelics grow these last few years as societal attitudes toward the use of these drugs change and their purported benefits for mental-health conditions make headlines. While learning more about this topic and the advancements being made is interesting, it is ...

MindMed Announces Pricing of Public Offering of Common Shares and Warrants Canada NewsWire NEW YORK , Sept. 27, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. ("MindMed") (NASDAQ: MNMD) (NEO: MMED), a clinical stage biopharmaceutical company developing novel ...